Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients

Zhang, Hongtao; Lin, Haibin; Mo, Xiaoqiong; Chen, Guoli; Lin, Lijun

doi:10.1007/s12032-013-0608-6

Cited by 11 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After that, the protein was visualized by DAB staining. Moreover, the degree of immunostaining was evaluated based on the percentage of positive tumor cells and the intensity of staining by two observers independently according to the methods described previously (Zhang et al 2013). The percentage scoring of immunoreactive tumor cells was: 0 (no positive tumor cells), 1 (< 10% positive tumor cells), 2 (10% to 50% positive tumor cells) and 3 (> 50% positive tumor cells).…”

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression [Retraction]

Yang

Hao

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Osteosarcoma is a malignant bone cancer that mainly affects children. SOX9 plays a key role in bone formation and osteosarcoma, and Claudin-8 (CLDN8), a tight junction protein, contributes to proliferation of osteosarcoma cells. The aim of this study was to investigate the relationship between SOX9 and CLDN8 in osteosarcoma. The expression levels of SOX9 and CLDN8 were determined in osteosarcoma specimens (n = 25) by qRT-PCR and Western blot analyses. The levels of SOX9 mRNA and protein were significantly higher in osteosarcoma tissues than those in adjacent non-tumor tissues, whereas the expression levels of CLDN8 mRNA and protein were significantly lower in osteosarcoma tissues. Immunohistochemical analysis showed the high expression of SOX9 in 56 out of 97 osteosarcoma tissues (57.7%). By contrast, the low expression of immunoreactive CLDN8 was observed in 62 of 97 osteosarcoma tissues (63.9%). There was the inverse correlation between the expression levels of SOX9 and CLDN8 proteins (R = −0.633, P < 0.001). The overall survival was poorer in the patients with high SOX9 expression. Subsequently, using two human osteosarcoma cell lines, we showed that knockdown of SOX9 inhibited cell proliferation and migration but promoted cell apoptosis. Importantly, knockdown of SOX9 increased the expression levels of CLDN8 protein. The transient luciferase-reporter assays suggest that SOX9 may inhibit the promoter activity of the CLDN8 gene in osteosarcoma cells. In conclusion, we provide the evidence demonstrating that SOX9 may promote cell growth by repressing the expression of CLDN8. Thus, SOX9 may be a therapeutic target for osteosarcoma.

show abstract

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression [Retraction]

Yang

Hao

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…In osteosarcoma, VEGF is a pro-angiogenic factor with a key role in pulmonary metastasis and poor prognosis [25,26]. The expression of PDGF-AA, endostatin, endothelin-1 and CD26 has been previously shown to be positively correlated with tumor progression in osteosarcoma [27,28,29,30] and the upregulation of serpin E1 and thrombospondin-1 in OS cells has been correlated with an increased risk of lung metastasis [31,32]. Additionally, Endo-Munoz L. et al, suggested an association between the metastatic behavior of OS and the activation of uPA axis carried by EVs at distant sites [33].…”

Section: Discussionmentioning

confidence: 99%

Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis

Perut

Roncuzzi

Zini

et al. 2019

Cancers

View full text Add to dashboard Cite

Angiogenesis involves a number of different players among which extracellular nanovesicles (EVs) have recently been proposed as an efficient cargo of pro-angiogenic mediators. Angiogenesis plays a key role in osteosarcoma (OS) development and progression. Acidity is a hallmark of malignancy in a variety of cancers, including sarcomas, as a result of an increased energetic metabolism. The aim of this study was to investigate the role of EVs derived from osteosarcoma cells on angiogenesis and whether extracellular acidity, generated by tumor metabolism, could influence EVs activity. For this purpose, we purified and characterized EVs from OS cells maintained at either acidic or neutral pH. The ability of EVs to induce angiogenesis was assessed in vitro by endothelial cell tube formation and in vivo using chicken chorioallantoic membrane. Our findings demonstrated that EVs derived from osteosarcoma cells maintained either in acidic or neutral conditions induced angiogenesis. The results showed that miRNA and protein content of EVs cargo are correlated with pro-angiogenic activity and this activity is increased by the acidity of tumor microenvironment. This study provides evidence that EVs released by human osteosarcoma cells act as carriers of active angiogenic stimuli that are able to promote endothelial cell functions relevant to angiogenesis.

show abstract

“…22 However, further studies are needed to clarify the potential correlations between ABO blood type, CD26 expression, and pancreatic diseases. Unlike in other cancers, 8,[25][26][27] in pancreatic malignancies, the expression status of CD26 was not associated with DFS or OS, which may be attributed to the high positive rate. However, when patients were classified into CD26 high-/low-expression groups, higher CD26 expression was correlated with poorer DFS and OS and was an independent predictive factor of OS.…”

Section: Discussionmentioning

confidence: 58%

<p>CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors</p>

Liang¹,

Tian²,

Ye³

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose Pancreatic cancer is associated with a high mortality rate owing to insufficient approaches for early diagnosis and the invasive biological behavior of the cancer. CD26 is a membrane-anchored protein involved in multiple physiological and pathological processes. Here, we investigated correlations between CD26 expression and clinicopathological features in patients with pancreatic tumors. Methods We collected 170 tumor tissue specimens and 138 paired paratumoral tissues from patients with pancreatic tumors and evaluated CD26 expression using immunohistochemistry. Results CD26 was expressed in 79.4% of pancreatic tumors, which was significantly ( P < 0.001) higher than that in paratumoral pancreatic tissues (23.2%). High expression of CD26 was correlated with ABO blood type ( P = 0.035), malignancy degree ( P = 0.001), CA199 ( P = 0.01), and CA242 ( P = 0.027). In pancreatic malignancies, CD26 expression was observed in 80.7% (130/161) of cases. Lower CD26 expression was correlated with longer disease-free survival ( P = 0.048) and overall survival ( P = 0.024) and was an independent predictor of overall survival (hazard ratio [HR]: 1.713; P = 0.042). Similar results were observed in pancreatic ductal adenocarcinoma (PDAC) tissues, and CD26 expression level (HR: 2.117; P = 0.008) was an independent predictor of overall survival in patients with PDAC. CD26 expression was significantly increased in pancreatic tumors and gradually increased with increasing malignancy degree, suggesting that CD26 may be involved in the tumorigenic proliferation of pancreatic tumors. Conclusion Therefore, CD26 is a potential marker for early diagnosis and a promising therapeutic target in pancreatic tumors.

show abstract

Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients

Cited by 11 publications

References 30 publications

Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression [Retraction]

Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression [Retraction]

Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis

<p>CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors</p>

Contact Info

Product

Resources

About